Real-World Study Shows Patients Treated with IMBRUVICA® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia

/PRNewswire/ --The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic...

Related Keywords

United States ,American ,Bryan Jacobs ,Imran Khan ,Christie Corbett ,None Of The Janssen Pharmaceutical Companies ,Atrium Health Levine Cancer Institute ,Janssen Biotech Inc ,American Society Of Hematology Annual Meeting ,Drug Administration ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Exchange Commission ,American Society Of Hematology ,Division Of Lymphoma Therapy Research ,Companies Of Johnson ,Department Of Hematologic Oncology ,Johnson ,Annual Meeting ,Clinical Director ,Lymphoma Therapy ,Hematologic Oncology ,Vice President ,Medical Affairs ,Janssen Biotech ,Cardiac Failure ,Sudden Death ,Primary Malignancies ,Lysis Syndrome ,Fetal Toxicity ,B Cell Malignancies ,Hepatic Impairment ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Janssen Research ,Annual Report ,Note Regarding Forward Looking ,World Comparison ,Next Treatment ,First Line Treatment ,Hematology Annual ,